share_log

綠葉製藥:自願性公告 - 創新制劑LY01610已完成III期臨床首例患者入組

LUYE PHARMA: VOLUNTARY ANNOUNCEMENT - FIRST PATIENT ENROLLED FOR PHASE 3 CLINICAL STUDY OF THE GROUP''S INNOVATIVE FORMULATION LY01610

香港交易所 ·  Mar 4 07:30
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more